Treeline Biosciences Holdings Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
169
- Latest Deal Type
-
Reverse Merger
- (Announced)
- Investors
-
14
Treeline Biosciences Holdings General Information
Description
Treeline Biosciences Holdings Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases. Its clinical-stage pipeline includes three Phase 1 programs, TLN-121, TLN-254, and TLN-372, and a fourth program, TLN-499, which is nearing clinical entry, all focused on oncology. Its preclinical pipeline includes programs in neurology, immunology, and oncology.
Contact Information
Website
www.treeline.bioCorporate Office
- 500 Arsenal Street
- 2nd Floor
- Watertown, MA 02472
- United States
Corporate Office
- 500 Arsenal Street
- 2nd Floor
- Watertown, MA 02472
- United States
Treeline Biosciences Holdings Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Reverse Merger | 20-Jul-2026 | Announced | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 01-Sep-2025 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A1) | 11-Oct-2022 | $261M | $473M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 09-Apr-2021 | $212M | $212M | Completed | Clinical Trials - General |
Treeline Biosciences Holdings Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Treeline Biosciences Holdings Comparisons
Industry
Financing
Details
Treeline Biosciences Holdings Competitors (76)
One of Treeline Biosciences Holdings’s 76 competitors is Kura Oncology, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kura Oncology | Formerly VC-backed | San Diego, CA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Pharmacyclics | Venture Capital-Backed | San Francisco, CA | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Treeline Biosciences Holdings Patents
Treeline Biosciences Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026183534-A1 | 2-cyclopropyl-3,3,9-trifluoro-l,2,3,4-tetrahydro- [1,4|oxazepino[2,3-ciouinolin-6(7h)-one bcl6 modulators | Pending | 28-Feb-2025 | ||
| WO-2026183536-A1 | Bcl6 bifunctional degraders and methods and intermediates for synthesizing the same | Pending | 28-Feb-2025 | ||
| WO-2026183449-A1 | Methods for treating cancer including a heterobifunctional degrader of bcl6 | Pending | 28-Feb-2025 | ||
| WO-2026183523-A1 | Methods for treating cancer including a heterobifunctional degrader of bcl6 | Pending | 28-Feb-2025 | ||
| WO-2026178027-A1 | Spirocyclic dihydropyranopyrimidine kras inhibitors | Pending | 18-Feb-2025 | C07D519/00 |
Treeline Biosciences Holdings Signals
Treeline Biosciences Holdings Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Exor | PE/Buyout | Minority | ||
| Fidelity | Corporation | Minority | ||
| Rock Springs Capital | Venture Capital | Minority | ||
| Access Industries | PE/Buyout | Minority | ||
| Aisling Capital | Venture Capital | Minority |
Treeline Biosciences Holdings Acquisitions (1)
Treeline Biosciences Holdings’s most recent deal was a Merger/Acquisition with Standard BioTools. The deal was made on 08-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Standard BioTools | 08-Jun-2026 | Merger/Acquisition | Discovery Tools (Healthcare) |
Treeline Biosciences Holdings FAQs
-
When was Treeline Biosciences Holdings founded?
Treeline Biosciences Holdings was founded in 2021.
-
Where is Treeline Biosciences Holdings headquartered?
Treeline Biosciences Holdings is headquartered in Watertown, MA.
-
What is the size of Treeline Biosciences Holdings?
Treeline Biosciences Holdings has 169 total employees.
-
What industry is Treeline Biosciences Holdings in?
Treeline Biosciences Holdings’s primary industry is Drug Discovery.
-
Is Treeline Biosciences Holdings a private or public company?
Treeline Biosciences Holdings is a Private company.
-
What is Treeline Biosciences Holdings’s current revenue?
The current revenue for Treeline Biosciences Holdings is .
-
How much funding has Treeline Biosciences Holdings raised over time?
Treeline Biosciences Holdings has raised $1.09B.
-
Who are Treeline Biosciences Holdings’s investors?
Exor, Fidelity, Rock Springs Capital, Access Industries, and Aisling Capital are 5 of 14 investors who have invested in Treeline Biosciences Holdings.
-
Who are Treeline Biosciences Holdings’s competitors?
Kura Oncology, Xenetic Biosciences, Pharmacyclics, NGM Biopharmaceuticals, and Sarepta Therapeutics are some of the 76 competitors of Treeline Biosciences Holdings.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process